Moreover, GRB2, an important upstream factor in MAPK/Erk signaling pathways, was reported to have implicated in resistance of ovarian cancer to cisplatin by activating MAPK/Erk signaling pathways42. This evidence concerns the gene GRB2 and ovarian carcinoma.